Charles River Laboratories International, Inc. (CRL) vs QIAGEN N.V. (QGEN)
- Charles River Laboratories International, Inc. CRL 299.77 −2.11%
- QIAGEN N.V. QGEN 46.13 −0.09%
Charles River Laboratories International, Inc. and QIAGEN N.V. are both Diagnostics & Research companies. Charles River Laboratories International, Inc. is the larger, with a market value of $14.6B against $9.5B — 1.5× the size. Charles River Laboratories International, Inc. has negative trailing earnings, so its P/E is not meaningful; QIAGEN N.V. trades at 23.6×. QIAGEN N.V. grew revenue faster over the last twelve months: 2.96% against −0.74%. QIAGEN N.V. has the higher net margin (19.5% vs −5.96%) and the higher return on invested capital (6.62% vs 1.07%). Across the 21 metrics below, QIAGEN N.V. leads on 18 and Charles River Laboratories International, Inc. on 3.
Valuation
Profitability
| Metric | CRL | QGEN | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 32.67% | 62.20% | 50.89% |
| Operating margin | 2.25% | 21.21% | (8.57%) |
| Net margin | (5.96%) | 19.49% | (6.37%) |
| Free cash flow margin | 9.27% | 20.98% | 0.00% |
| Return on equity | (7.69%) | 11.93% | (2.92%) |
| Return on assets | (3.16%) | 6.99% | (6.71%) |
| Return on invested capital | 1.07% | 6.62% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack